JP5507852B2 - 水性保湿剤及び潤滑剤並びにその使用 - Google Patents
水性保湿剤及び潤滑剤並びにその使用 Download PDFInfo
- Publication number
- JP5507852B2 JP5507852B2 JP2008557410A JP2008557410A JP5507852B2 JP 5507852 B2 JP5507852 B2 JP 5507852B2 JP 2008557410 A JP2008557410 A JP 2008557410A JP 2008557410 A JP2008557410 A JP 2008557410A JP 5507852 B2 JP5507852 B2 JP 5507852B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- sperm
- viability
- certain embodiments
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000314 lubricant Substances 0.000 title claims description 65
- 239000003906 humectant Substances 0.000 title description 8
- 239000000203 mixture Substances 0.000 claims description 291
- 210000004027 cell Anatomy 0.000 claims description 78
- 230000035899 viability Effects 0.000 claims description 70
- 239000003795 chemical substances by application Substances 0.000 claims description 65
- 210000001519 tissue Anatomy 0.000 claims description 64
- 210000000287 oocyte Anatomy 0.000 claims description 62
- 230000004720 fertilization Effects 0.000 claims description 54
- 210000002257 embryonic structure Anatomy 0.000 claims description 38
- 239000003755 preservative agent Substances 0.000 claims description 37
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 26
- 239000003855 balanced salt solution Substances 0.000 claims description 20
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 20
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 19
- 239000011575 calcium Substances 0.000 claims description 19
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 16
- 239000002953 phosphate buffered saline Substances 0.000 claims description 16
- 210000001215 vagina Anatomy 0.000 claims description 16
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 15
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 15
- 238000012423 maintenance Methods 0.000 claims description 14
- 229910001414 potassium ion Inorganic materials 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 11
- -1 PCAGH Chemical compound 0.000 claims description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 10
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 10
- 229960002216 methylparaben Drugs 0.000 claims description 10
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 8
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 8
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910001415 sodium ion Inorganic materials 0.000 claims description 7
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 229910001424 calcium ion Inorganic materials 0.000 claims description 5
- 239000006260 foam Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims description 2
- 229920000189 Arabinogalactan Polymers 0.000 claims description 2
- 239000001904 Arabinogalactan Substances 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 235000019312 arabinogalactan Nutrition 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 64
- 238000003860 storage Methods 0.000 description 38
- 239000012190 activator Substances 0.000 description 37
- 239000002609 medium Substances 0.000 description 36
- 210000000056 organ Anatomy 0.000 description 36
- 239000003623 enhancer Substances 0.000 description 32
- 230000006870 function Effects 0.000 description 28
- 239000012472 biological sample Substances 0.000 description 23
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 22
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 22
- 238000000338 in vitro Methods 0.000 description 21
- 239000013028 medium composition Substances 0.000 description 20
- 210000001161 mammalian embryo Anatomy 0.000 description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 18
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 235000013601 eggs Nutrition 0.000 description 18
- 230000035558 fertility Effects 0.000 description 17
- 229920001542 oligosaccharide Polymers 0.000 description 16
- 150000002482 oligosaccharides Chemical class 0.000 description 16
- 108090000288 Glycoproteins Proteins 0.000 description 15
- 102000003886 Glycoproteins Human genes 0.000 description 15
- 238000012258 culturing Methods 0.000 description 15
- 230000003993 interaction Effects 0.000 description 15
- 150000002500 ions Chemical class 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 14
- 229910052791 calcium Inorganic materials 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000001574 biopsy Methods 0.000 description 12
- 244000005706 microflora Species 0.000 description 12
- 210000000582 semen Anatomy 0.000 description 12
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 11
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 11
- 229960001948 caffeine Drugs 0.000 description 11
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 11
- 150000001720 carbohydrates Chemical class 0.000 description 11
- 239000011777 magnesium Substances 0.000 description 11
- 229910052749 magnesium Inorganic materials 0.000 description 11
- 210000003899 penis Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 10
- 241000282412 Homo Species 0.000 description 10
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 10
- 229910002091 carbon monoxide Inorganic materials 0.000 description 10
- 230000003915 cell function Effects 0.000 description 10
- 230000002708 enhancing effect Effects 0.000 description 10
- 230000035479 physiological effects, processes and functions Effects 0.000 description 10
- 230000035790 physiological processes and functions Effects 0.000 description 10
- 230000001150 spermicidal effect Effects 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 150000004676 glycans Chemical class 0.000 description 9
- 230000009027 insemination Effects 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 230000002335 preservative effect Effects 0.000 description 9
- 239000000186 progesterone Substances 0.000 description 9
- 229960003387 progesterone Drugs 0.000 description 9
- 239000002516 radical scavenger Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 230000032258 transport Effects 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 8
- 102000001974 Hyaluronidases Human genes 0.000 description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 8
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 8
- 229940095074 cyclic amp Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000004899 motility Effects 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 108010088751 Albumins Proteins 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 108010003272 Hyaluronate lyase Proteins 0.000 description 7
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 239000001569 carbon dioxide Substances 0.000 description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- 229960002773 hyaluronidase Drugs 0.000 description 7
- 230000001568 sexual effect Effects 0.000 description 7
- 210000004340 zona pellucida Anatomy 0.000 description 7
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical class NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- 206010011732 Cyst Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 6
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 description 6
- 208000031513 cyst Diseases 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000003296 saliva Anatomy 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 5
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 5
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 229960003943 hypromellose Drugs 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 238000005057 refrigeration Methods 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000736262 Microbiota Species 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- 235000010338 boric acid Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 108010044426 integrins Proteins 0.000 description 4
- 235000015110 jellies Nutrition 0.000 description 4
- 239000008274 jelly Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000005461 lubrication Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 229960003966 nicotinamide Drugs 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 239000006179 pH buffering agent Substances 0.000 description 4
- 229940101267 panthenol Drugs 0.000 description 4
- 235000020957 pantothenol Nutrition 0.000 description 4
- 239000011619 pantothenol Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 239000003223 protective agent Substances 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 235000019192 riboflavin Nutrition 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 239000002151 riboflavin Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 238000004017 vitrification Methods 0.000 description 4
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 3
- 208000034656 Contusions Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000007990 PIPES buffer Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940035674 anesthetics Drugs 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 229960002645 boric acid Drugs 0.000 description 3
- 229940105305 carbon monoxide Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002577 cryoprotective agent Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000003193 general anesthetic agent Substances 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 3
- 229940099552 hyaluronan Drugs 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000001050 lubricating effect Effects 0.000 description 3
- 229910001437 manganese ion Inorganic materials 0.000 description 3
- 238000013208 measuring procedure Methods 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000000426 osmoregulatory effect Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229940037179 potassium ion Drugs 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229960004599 sodium borate Drugs 0.000 description 3
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- 238000007614 solvation Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 230000019100 sperm motility Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YTPMCWYIRHLEGM-BQYQJAHWSA-N 1-[(e)-2-propylsulfonylethenyl]sulfonylpropane Chemical compound CCCS(=O)(=O)\C=C\S(=O)(=O)CCC YTPMCWYIRHLEGM-BQYQJAHWSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 150000000994 L-ascorbates Chemical class 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000030120 acrosome reaction Effects 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229920000223 polyglycerol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000029783 sperm-egg recognition Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- IAJILQKETJEXLJ-KLVWXMOXSA-N (2s,3r,4r,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-KLVWXMOXSA-N 0.000 description 1
- AZUXKVXMJOIAOF-UHFFFAOYSA-N 1-(2-hydroxypropoxy)propan-2-ol Chemical compound CC(O)COCC(C)O AZUXKVXMJOIAOF-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 108010053481 Antifreeze Proteins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102100037677 Cell surface hyaluronidase Human genes 0.000 description 1
- 101710125063 Cell surface hyaluronidase Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108050009363 Hyaluronidases Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229960004956 glycerylphosphorylcholine Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940113601 irrigation solution Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940052665 nadh Drugs 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229960003753 nitric oxide Drugs 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 230000027272 reproductive process Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000009303 sperm storage Effects 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Reproductive Health (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本発明の一部は、生存能維持剤、及び/又は、受精及び他の生理機能の向上剤を潤滑剤及び保湿剤に使用することにより、生体細胞及び組織の生存能力が改善されると共に、それらの機能も改善されるという、本発明者等の予期せぬ発見の結果である。例えば、本発明者等は、精子を種々のバッファー中で30分間インキュベートした後、FACSアッセイ(実施例3に記載)を用いて生存能力を分析したところ、生存能維持剤として二価イオンを含有する潤滑剤(組成物1、組成物2、及び組成物3)と共にインキュベートした精子の生存能力は、それを含有しない潤滑剤(殺精子性として公知の潤滑剤であるK−Yゼリー(K-Y Jelly)等(18−22))と比べて殆んど低下しないことを見出した(表1)。更に驚くべき結果として、本発明者等は、潤滑剤組成物中に生存能維持剤として二価イオンを加えることにより、市販の非殺精子性潤滑剤(Pre-Seed等)と比較しても精子生存能力が増強されることを見出した。グリセロール、プロピレングリコール、ポリエチレングリコール等、他の幾つかの潤滑性剤を主とする潤滑剤も、生存能維持剤と組み合わせた場合に、同様の結果が得られた。
本発明は更に、媒体(培地)として使用される組成物、及び関連する使用方法を提供する。
ある実施形態によれば、本発明の組成物は、制御された温度、加熱、冷蔵、凍結又はガラス化状態における貯蔵中に精子、卵母細胞、胚、細胞又は組織を保存するための貯蔵媒体として使用され、貯蔵溶液基剤中に1又は2以上の生存能維持剤を含んでなる。本発明の組成物は、細胞機能を維持し又は増進するのに適した範囲のpH、重量オスモル濃度及び粘度を有することが好ましい。ある態様によれば、本発明の組成物は、生理機能を増進する剤を含んでなる。かかる特定の実施形態によれば、生理機能を増進する剤は、精子活性化剤、エネルギー増強剤、スカベンジャー、受精促進剤又はそれらの混合物を含んでなる。ある実施形態によれば、本発明の組成物は、細胞、精子、卵母細胞、胚、又は組織の生存能力又は機能に影響するある種の防腐剤及びバッファーを全く含有せず、或いは実質的に含有しない。かかる防腐剤の例としては、これらに限定されるものではないが、EDTA、環状RGDペプチド及び細胞−細胞及び細胞−細胞間質の相互作用を阻害する、特定の糖タンパク質、糖類又はオリゴ糖が挙げられる。
コンドームは、米国特許分類マニュアル604/349に記載のように、通常、陰茎からの精液を捕集するべく構成された容器を指す。コンドームは陰茎に被せることができ、別の設計の物は、膣内に挿入することができる。コンドームは通常は柔軟性を有し、放出された精液を受容するべく、陰茎周囲に密着するように成形及び設計されている。通常は開放端から閉鎖端に伸長するチューブ様構造として成形され、中央に延在部を有する。コンドームは内部及び外部表面を有する。
NaH2PO4(無水) 約0.32g
NaCl 約9g
蒸留水中で混合して溶解させ、pHを8.0に調節する。
蒸留水を加えて、最終容積を約1000mLにする。
組成物2=0.75%(w/v)ヒプロメロース
溶液A:
Na2HPO4(無水) 約0.234g
NaH2PO4(無水) 約0.048g
蒸留水を加えた最終容積 約5.0mL
溶液B:
CaCl22H2O 約0.013g
KCl 約0.026g
MgCl26H2O 約0.018g
NaCl 約0.80g
蒸留水を加えた最終容積 約5.0mL
1. S. Greaves and C. Wang. A fertile field. Nat Cell Biol. 2002 Oct;4 Suppl:S2
2. A. Glasier. Contraception - Past and future. Nat Cell Biol. 2002 Oct;4 Suppl:S3-S6
3. P. M. Wassarman. Channels of communication in the ovary. Nat Cell Biol. 2002 Oct;4 Suppl:S7-S9
4. L. R. Fraser ART: Boon or bane? Nat Cell Biol. 2002 Oct;4 Suppl:S10-S13
5. R. M. L. Winston and K. Hardy. Are we ignoring potential dangers of in vitro fertilization and related treatments? Nat Cell Biol. 2002 Oct;4 Suppl:S14-S18
6. G. P. Schatten. Safeguarding ART. Nat Cell Biol. 2002 Oct;4 Suppl:S19-S22
7. R. A. Charo, J. D. Children by choice: reproductive technologies and the boundaries of personal autonomy. Nat Cell Biol. 2002 Oct;4 Suppl:S23-S28
8. P. Katz, R. Nachtigall and J. Showstack. The economic impact of the assisted reproductive technologies. Nat Cell Biol. 2002 Oct;4 Suppl:S29-S32
9. R. M. Sharpe and S. Franks. Environment, lifestyle and infertility − an intergenerational issue. Nat Cell Biol. 2002 Oct;4 Suppl:S33-S40
10. M. M. Matzuk and D. J. Lamb Genetic dissection of mammalian fertility pathways. Nat Cell Biol. 2002 Oct;4 Suppl:S41-S49
11. M. D. Champion and R. S. Hawley. Playing for half the deck: the molecular biology of meiosis. Nat Cell Biol. 2002 Oct;4 Suppl:S50-S56
12. J. P. Evans and H. M. Florman. The state of the union: the cell biology of fertilization. Nat Cell Biol. 2002 Oct;4 Suppl:S57-S63
13. Butler D. The fertility riddle. Nature. 2004 Nov 4;432(7013):38-9.
14. Powell K. Skeptics demand duplication of controversial fertility claim. Nat Med. 2005 Sep;11(9):911.
15. Kirichok Y, Navarro B, Clapham DE. Whole-cell patch-clamp measurements of spermatozoa reveal an alkaline-activated Ca2+ channel. Nature. 2006,9;439(7077):737.
16. Powell K. Fertility treatments: Seeds of doubt. Nature. 2003 Apr 17;422(6933):656-8.
17. Chen Y, Cann MJ, Litvin TN, Iourgenko V, Sinclair ML, Levin LR, Buck J. Soluble adenylyl cyclase as an evolutionarily conserved bicarbonate sensor. Science. 2000 Jul 28;289(5479):625-8.
18. Goldenberg RL, White R. The effect of vaginal lubricants on sperm motility in vitro. Fertil Steril. 1975 Sep;26(9):872-3.
19. Kutteh WH, Chao CH, Ritter JO, Byrd W. Vaginal lubricants for the infertile couple: effect on sperm activity, Int J Fertil Menopausal Stud. 1996 Jul-Aug;41(4):400-4.
20. Frishman GN, Luciano AA, Maier DB. Evaluation of Astroglide, a new vaginal lubricant: effects of length of exposure and concentration on sperm motility. Fertil Steril. 1992 Sep;58(3):630-2.
21. Anderson L, Lewis SE, McClure N. The effects of coital lubricants on sperm motility in vitro. Hum Reprod. 1998 Dec;13(12):3351-6.
22. Tagatz GE, Okagaki T, Sciarra JJ. The effect of vaginal lubricants on sperm motility and viability in vitro. Am J Obstet Gynecol. 1972 May 1;113 (1):88-90.
23. Visconti et al., Novel signaling pathways involved in sperm acquisition of fertilizing capacity, Journal of Reproductive Immunology, 2002, 53, 133-150.
24. Glander HJ, Schaller J. Binding of annexin V to plasma membranes of human spermatozoa: a rapid assay for detection of membrane changes after cryostorage. Mol Hum Reprod. 1999 Feb;5(2):109-15.
Claims (14)
- 膣に使用される局所潤滑剤組成物であって、
(a)メチルパラベンと、グリセロール、アラビノガラクタン、PCAGH、デキストラン、ポリアクリル酸、カルボマー、ポリエチレンオキシド、エチレンオキシドとプロピレンオキシドのコポリマー、メチルセルロース、ヒドロキシメチルセルロース、ヒドロキシエチルセルロース、ヒドロキシプロピルメチルセルロース、ポリエチレングリコール、ヒドロキシプロピルグアール、及び植物油から選択される1又は2以上とを含む潤滑性剤を、水性平衡塩溶液中に含有する水性潤滑剤基剤、及び
(b)カルシウム、ナトリウム、カリウム及びマグネシウムのイオンを含有する生存能維持剤
を含んでなるとともに、
pHが5.0〜9.0であり、重量オスモル濃度が200〜700mOsm/kgであり、細胞、精子、卵母細胞、胚又は組織の生存能力に影響を及ぼす特定の防腐剤又はバッファーを全く含まないか、或いは実質的に含まない、組成物。 - 前記潤滑性剤がメチルパラベンとヒドロキシプロピルメチルセルロースとを含有する、請求項1に記載の組成物。
- 前記潤滑性剤がメチルパラベンとグリセロールとを含有する、請求項1に記載の局所潤滑剤組成物。
- 前記潤滑性剤がメチルパラベンとヒドロキシプロピルメチルセルロースとグリセロールとからなる、請求項1に記載の組成物。
- 前記生存能維持剤の濃度が0.1mM〜5.0mMである、請求項1〜4の何れか一項に記載の局所潤滑剤組成物。
- (a)リン酸緩衝食塩水と、(b)カルシウム、ナトリウム、カリウム及びマグネシウムのイオンと、(c)ヒドロキシプロピルメチルセルロースと、(d)メチルパラベンと、(e)グリセロールと、(f)抗酸化剤とを含む、膣に使用される組成物であって、細胞、精子、卵母細胞、胚又は組織の生存能力に影響を及ぼす特定の防腐剤又はバッファーを全く含まないか、或いは実質的に含まない、組成物。
- pHが5.0〜9.0である請求項6の組成物。
- pHが7.0〜8.5である請求項1〜7の何れか一項に記載の組成物。
- EDTAを含有しない請求項1〜8の何れか一項に記載の組成物。
- 溶液、ゲル、フォーム又はクリームの形態である請求項1〜9の何れか一項に記載の組成物。
- 重量オスモル濃度が250〜500mOsm/kgである請求項1〜10の何れか一項に記載の組成物。
- 重量オスモル濃度が300〜400mOsm/kgである請求項11に記載の組成物。
- 容器に包装されてなる請求項1〜12の何れか一項に記載の組成物。
- 卵母細胞の受精を容易にするために使用される請求項1〜13の何れか一項に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/364,200 US8703198B2 (en) | 2005-03-02 | 2006-03-01 | Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof |
US11/364,200 | 2006-03-01 | ||
PCT/US2007/005407 WO2007103194A2 (en) | 2006-03-01 | 2007-02-28 | Aqueous moisturizers and lubricants and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009528372A JP2009528372A (ja) | 2009-08-06 |
JP2009528372A5 JP2009528372A5 (ja) | 2010-04-22 |
JP5507852B2 true JP5507852B2 (ja) | 2014-05-28 |
Family
ID=38461956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008557410A Active JP5507852B2 (ja) | 2006-03-01 | 2007-02-28 | 水性保湿剤及び潤滑剤並びにその使用 |
Country Status (12)
Country | Link |
---|---|
US (3) | US8703198B2 (ja) |
EP (1) | EP1996159A2 (ja) |
JP (1) | JP5507852B2 (ja) |
KR (1) | KR101490851B1 (ja) |
AU (1) | AU2007224123A1 (ja) |
BR (1) | BRPI0708411B1 (ja) |
CA (1) | CA2644096C (ja) |
IL (1) | IL193685A (ja) |
MX (1) | MX2008011187A (ja) |
NZ (1) | NZ596263A (ja) |
SG (2) | SG170063A1 (ja) |
WO (1) | WO2007103194A2 (ja) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100233295A1 (en) * | 2005-03-02 | 2010-09-16 | Vibha Gupta | Aqueous moisturizers and lubricants and uses thereof |
US20080193489A1 (en) * | 2007-02-13 | 2008-08-14 | Robert De Armond | Personal Lubricant Compositions That Are Free Of Glycerin and Parabens |
GB0722507D0 (en) * | 2007-11-19 | 2007-12-27 | Zhao Xiaobin | Hyaluronic acid personal lubricant |
US8980840B2 (en) * | 2009-01-13 | 2015-03-17 | Schepens Eye Research Institute | Therapeutic modulation of vaginal epithelium boundary lubrication |
GB0905677D0 (en) | 2009-04-01 | 2009-05-20 | Yes Syzygy Ltd | Intimate lubrication kit |
IT1405998B1 (it) * | 2010-12-09 | 2014-02-06 | Bionest Ltd | Gel polifunzionale contro la secchezza vaginale ad effetto diretto e ritardato |
WO2012092990A2 (de) * | 2011-01-05 | 2012-07-12 | Udo Wenske | Medizinprodukt zur verbesserung der konzeptionsfähigkeit eines säugetiers |
CA2830298C (en) * | 2011-03-17 | 2016-08-16 | Transdermal Biotechnology, Inc. | Topical nitric oxide systems comprising lecithin and methods of use thereof |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
CA2925546C (en) | 2012-10-29 | 2022-06-14 | The University Of North Carolina At Chapel Hill | Methods and compositions for treating mucosal tissue disorders |
US20140178314A1 (en) * | 2012-12-19 | 2014-06-26 | The Procter & Gamble Company | Compositions and/or articles with improved solubility of a solid active |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
JP5904369B2 (ja) * | 2012-12-28 | 2016-04-13 | 国立大学法人広島大学 | 精子保存液、精子保存方法及び人工授精方法 |
CA2905988C (en) | 2013-03-14 | 2021-04-06 | Church & Dwight Co., Inc. | Aqueous lubricant composition comprising hyaluronic acid |
KR101470282B1 (ko) * | 2013-10-01 | 2014-12-05 | 최원석 | 소금 및 당의 조합물을 유효성분으로 함유하는 질이완증 또는 질건조증 예방 및 치료용 약학 조성물 및 이의 용도 |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
KR20170040209A (ko) | 2014-07-29 | 2017-04-12 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 경피 크림 |
US10952979B2 (en) * | 2014-12-19 | 2021-03-23 | Good Clean Love, Inc. | Topical fertility promoting product and manufacturing method |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017064482A1 (en) * | 2015-10-14 | 2017-04-20 | The Royal Veterinary College | Methods and compositions |
DE102015121701A1 (de) | 2015-12-14 | 2016-04-07 | Ritex GmbH | Verwendung von Dimeticon |
ITUA20161288A1 (it) * | 2016-02-19 | 2017-08-19 | P L Pharma S R L | Composizione per favorire la risalita degli spermatozoi nel canale cervico-vaginale umano. |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
WO2017176768A1 (en) * | 2016-04-04 | 2017-10-12 | Imquest Biosciences, Inc. | Low osmolality gel composition |
AU2016423774B2 (en) * | 2016-09-22 | 2019-11-21 | Colgate-Palmolive Company | Personal care gel and method |
EP3541401A4 (en) | 2016-11-17 | 2020-07-29 | Renovion, Inc. | TREATMENT OF AIRWAY DISEASES AND INFECTIONS WITH GLUTATHION COMPOSITIONS |
CN111479463A (zh) * | 2017-10-30 | 2020-07-31 | Abs全球公司 | 用于改善的配子活力和功能的组合物和方法 |
SG11202004540QA (en) | 2017-11-17 | 2020-06-29 | Renovion Inc | Stable ascorbic acid compositions and methods of using the same |
KR20200009419A (ko) | 2018-07-19 | 2020-01-30 | 주식회사 홉앤조이 | 질 윤활제 조성물 |
CN109554337B (zh) * | 2018-12-24 | 2022-03-15 | 内蒙古赛科星家畜种业与繁育生物技术研究院有限公司 | 透明质酸的用途 |
US11590073B2 (en) | 2020-06-09 | 2023-02-28 | The Procter & Gamble Company | Methods and compositions for reducing the feeling of vaginal dryness |
EP4014974A1 (en) * | 2020-12-17 | 2022-06-22 | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth | A composition for use in the treatment of infertility |
KR102461196B1 (ko) * | 2021-08-24 | 2022-10-31 | 주식회사 그리니쉬 | 정자 활성 효과를 갖는 윤활 조성물 |
WO2024052570A1 (en) * | 2022-09-09 | 2024-03-14 | Julius-Maximilians-Universität Würzburg | Method for the preservation of functional gametes |
CN117258052B (zh) * | 2023-11-22 | 2024-03-01 | 广州双一乳胶制品有限公司 | β-1,3-葡聚糖在制备避孕套用水性润滑剂中的应用 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3719594A (en) * | 1971-06-17 | 1973-03-06 | Nat Waterpure Corp | Water-softening unit |
US4184974A (en) * | 1974-05-16 | 1980-01-22 | Leuven James W Van | Liquid biocidal compositions comprising a mixture of silver ions and sodium pectate |
US3965908A (en) * | 1975-01-02 | 1976-06-29 | Posthuma Albert E | Synthetic physiological mucus |
US3965906A (en) * | 1975-02-24 | 1976-06-29 | Colgate-Palmolive Company | Absorbent article with pattern and method |
US4232003A (en) * | 1975-11-26 | 1980-11-04 | Posthuma Albert E | Synthetic physiological mucus |
US4039662A (en) * | 1975-12-04 | 1977-08-02 | Alcon Laboratories, Inc. | Ophthalmic solution |
US4128631A (en) * | 1977-02-16 | 1978-12-05 | General Mills Chemicals, Inc. | Method of imparting lubricity to keratinous substrates and mucous membranes |
US4120949A (en) * | 1977-10-05 | 1978-10-17 | Cooper Laboratories, Inc. | Ophthalmic solution |
US4267268A (en) * | 1979-03-12 | 1981-05-12 | Nelson Jr Robert A | Spermatozoa extenders |
US4527988A (en) * | 1982-09-20 | 1985-07-09 | Lutz Peter L | Porous contraceptive device with an interstitial liquid |
US5209927A (en) * | 1985-01-23 | 1993-05-11 | Alcon Laboratories, Inc. | Ophthalmic solution |
US4670256A (en) * | 1985-09-23 | 1987-06-02 | V. Valhalla Corp. | Vaginal conditioning for sexual activity |
EP0238218B1 (en) * | 1986-03-12 | 1990-09-26 | Euroceltique S.A. | Contraceptive composition |
US4883658A (en) * | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
US4981686A (en) * | 1987-05-18 | 1991-01-01 | Hardy Robert E | Personal lubricant |
US4923699A (en) * | 1988-06-03 | 1990-05-08 | Kaufman Herbert E | Eye treatment suspension |
US5015474A (en) * | 1988-11-22 | 1991-05-14 | Parnell Pharmaceuticals, Inc. | Composition for imparting moisture to a substrate |
US5128132A (en) * | 1988-11-22 | 1992-07-07 | Parnell Pharmaceuticals, Inc. | Eriodictyon compositions and methods for treating internal mucous membranes |
IL92351A (en) * | 1988-11-29 | 1994-02-27 | Allergan Inc Irvine | Optimal aqueous solutions containing stabilized chlorine acid and inorganic salt |
US5013714A (en) * | 1988-12-15 | 1991-05-07 | Lindstrom Richard L | Viscoelastic solution |
US5545673A (en) * | 1989-06-06 | 1996-08-13 | Kelly; Patrick D. | Method for reducing risk of infection by sexually transmitted viruses |
US5208031A (en) * | 1989-06-06 | 1993-05-04 | Kelly Patrick D | Sexual lubricants containing zinc as an anti-viral agent |
DK0500807T3 (da) | 1989-10-31 | 2000-02-07 | Columbia Lab Inc | Præparat og fremgangsmåde til befugtning af væv |
US5102783A (en) * | 1990-01-12 | 1992-04-07 | Vetrepharm, Inc. | Composition and method for culturing and freezing cells and tissues |
US5342617A (en) * | 1990-12-03 | 1994-08-30 | Medical Polymers, Inc. | Water-based human tissue lubricant |
US5980477A (en) * | 1991-07-29 | 1999-11-09 | Patrick Kelly | Genital lubricants with zinc salts as anti-viral additives |
US5389657A (en) * | 1993-02-01 | 1995-02-14 | Free Radical Sciences Corporation | Method for treating infertility |
US6321750B1 (en) * | 1993-05-03 | 2001-11-27 | Patrick D. Kelly | Condom lubricants with zinc salts as anti-viral additives |
CA2125060C (en) * | 1993-07-02 | 1999-03-30 | Henry P. Dabrowski | Ophthalmic solution for artificial tears |
US6200557B1 (en) * | 1993-07-06 | 2001-03-13 | Perry A. Ratcliff | Method of treating HIV by a topical composition |
GR940100370A (el) * | 1993-07-28 | 1994-07-26 | Johnson & Johnson Consumer Products Inc. | Μια σπερμοκτονος λιπαντικη αντι-ιου συνθεση και μεθοδος χρησης της. |
US5592949A (en) * | 1994-06-29 | 1997-01-14 | Moench; Thomas R. | Device for acidic buffering and method for inactivation of pathogens |
US5895645A (en) * | 1995-01-31 | 1999-04-20 | Bausch & Lomb Incorporated | Opthalmic solution for artificial tears |
US5952006A (en) | 1995-09-29 | 1999-09-14 | L.A.M. Pharmaceuticals, Llc | Drug preparations for treating impotency |
DE69637625D1 (de) * | 1995-10-19 | 2008-09-18 | Bio Origyn Llc | Methoden und zusammensetzungen, die das ueberleben und die funktion von keimbahnzellen und embryonen verbessern |
US5702218A (en) * | 1995-12-13 | 1997-12-30 | Onofrio; Daniel | Fastener |
US5577514A (en) * | 1995-12-18 | 1996-11-26 | Zimmerman; Arnold S. | Condom |
US5879877A (en) | 1996-02-09 | 1999-03-09 | Advanced Reproduction Technologies Inc. | Use of arabinogalactan in a sperm wash product |
US5897987A (en) | 1996-03-25 | 1999-04-27 | Advanced Reproduction Technologies, Inc. | Use of arabinogalactan in cell cryopreservation media |
AU714797B2 (en) * | 1996-06-14 | 2000-01-13 | Mcneil-Ppc, Inc. | Moisture containing compositions that are spreadable onto and adherable to biomembranes, methods of making and use thereof |
US6596777B1 (en) * | 1997-05-29 | 2003-07-22 | Mcneil-Ppc, Inc. | Moisture containing compositions that are spreadable onto and adherable to biomembranes |
US5885591A (en) * | 1996-07-02 | 1999-03-23 | Johnson & Johnson Consumer Products, Inc. | Personal lubricant compositions |
US5800807A (en) * | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
US5857959A (en) * | 1997-02-03 | 1999-01-12 | Veos France Eurl | Conception kit |
US5899848A (en) * | 1997-07-14 | 1999-05-04 | Haubrich; Mark A. | Device and process for artificial insemination of animals |
US6277365B1 (en) * | 1997-09-18 | 2001-08-21 | Bausch & Lomb Incorporated | Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent |
US5902593A (en) * | 1997-10-01 | 1999-05-11 | Kent; Frances B. | Topically applied personal lubricant containing benzalkonium chloride as the active ingredient |
WO2000029030A1 (en) * | 1998-11-13 | 2000-05-25 | Continental Projects Limited | Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions |
US6139848A (en) * | 1999-02-12 | 2000-10-31 | Mcneil-Ppc, Inc. | Personal lubricant compositions |
US6281251B1 (en) * | 1999-03-22 | 2001-08-28 | University Of Kentucky Research Foundation | Iodo-nonoxynol-9-derivatives and methods for their use |
US6231849B1 (en) * | 1999-03-25 | 2001-05-15 | George A. Schiller | Simulated seminal fluid |
US6428791B1 (en) * | 1999-04-13 | 2002-08-06 | Alphamed Pharmace Vticals, Corp | Lubrication composition |
FR2793495B1 (fr) * | 1999-05-14 | 2001-08-10 | Imv Technologies | Dilueur pour la cryoconservation de spermatozoides de bovins |
US6864046B1 (en) * | 2000-03-01 | 2005-03-08 | Texas Tech University | Method for collecting and preserving semen |
RU2274442C2 (ru) * | 2000-03-07 | 2006-04-20 | Раш-Презбитериан-Ст. Лук'С Медикал Сентер | Композиции и способы улавливания и инактивации патогенных микроорганизмов и сперматозоидов |
AU2001273636A1 (en) * | 2000-06-27 | 2002-01-08 | Qualilife Pharmaceuticals Inc. | Compositions and methods for treating females sexual response |
US6365200B1 (en) * | 2000-07-19 | 2002-04-02 | Jason C. Birnholz | Topical skin sensitizer |
AR035509A1 (es) * | 2000-12-21 | 2004-06-02 | Alcon Inc | Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento |
JP4651944B2 (ja) * | 2002-02-07 | 2011-03-16 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 殺精子剤および殺菌剤からの粘膜刺激の予防のための亜鉛塩組成物 |
MXPA04009036A (es) * | 2002-03-18 | 2005-01-25 | Pfizer Prod Inc | Uso de agonistas del receptor ep4 selectivos para el tratamiento de la insuficiencia hepatica, perdida de permeabilidad del ductus arterioso, glaucoma o hipertension ocular. |
US6610331B1 (en) * | 2002-05-30 | 2003-08-26 | Scott M. Sweazy | Fertility kit |
US20050076917A1 (en) * | 2003-10-10 | 2005-04-14 | Biofilm Ip, Llc. | Lubricated condom |
-
2006
- 2006-03-01 US US11/364,200 patent/US8703198B2/en active Active
-
2007
- 2007-02-28 BR BRPI0708411-0A patent/BRPI0708411B1/pt not_active IP Right Cessation
- 2007-02-28 JP JP2008557410A patent/JP5507852B2/ja active Active
- 2007-02-28 SG SG201101510-4A patent/SG170063A1/en unknown
- 2007-02-28 MX MX2008011187A patent/MX2008011187A/es active IP Right Grant
- 2007-02-28 SG SG10201407894PA patent/SG10201407894PA/en unknown
- 2007-02-28 KR KR1020087023988A patent/KR101490851B1/ko active IP Right Grant
- 2007-02-28 CA CA2644096A patent/CA2644096C/en active Active
- 2007-02-28 EP EP07752128A patent/EP1996159A2/en not_active Withdrawn
- 2007-02-28 WO PCT/US2007/005407 patent/WO2007103194A2/en active Application Filing
- 2007-02-28 AU AU2007224123A patent/AU2007224123A1/en not_active Abandoned
-
2008
- 2008-08-25 IL IL193685A patent/IL193685A/en active IP Right Grant
-
2011
- 2011-11-07 NZ NZ596263A patent/NZ596263A/xx unknown
-
2014
- 2014-01-21 US US14/160,143 patent/US20140147520A1/en not_active Abandoned
- 2014-10-29 US US14/526,719 patent/US20150051169A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2009528372A (ja) | 2009-08-06 |
US20150051169A1 (en) | 2015-02-19 |
SG170063A1 (en) | 2011-04-29 |
CA2644096C (en) | 2016-09-06 |
EP1996159A2 (en) | 2008-12-03 |
US8703198B2 (en) | 2014-04-22 |
SG10201407894PA (en) | 2014-12-30 |
IL193685A (en) | 2016-02-29 |
US20140147520A1 (en) | 2014-05-29 |
KR20090018601A (ko) | 2009-02-20 |
US20060204557A1 (en) | 2006-09-14 |
WO2007103194A2 (en) | 2007-09-13 |
CA2644096A1 (en) | 2007-09-13 |
AU2007224123A1 (en) | 2007-09-13 |
BRPI0708411A2 (pt) | 2011-05-31 |
MX2008011187A (es) | 2008-12-18 |
NZ596263A (en) | 2013-05-31 |
WO2007103194A3 (en) | 2007-11-22 |
KR101490851B1 (ko) | 2015-02-06 |
IL193685A0 (en) | 2009-08-03 |
BRPI0708411B1 (pt) | 2023-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5507852B2 (ja) | 水性保湿剤及び潤滑剤並びにその使用 | |
Skidmore | Reproduction in dromedary camels: an update | |
JP4421681B2 (ja) | 生殖細胞および胚の生存および機能を改善する方法および組成物 | |
US20100233295A1 (en) | Aqueous moisturizers and lubricants and uses thereof | |
JP2008536524A (ja) | 不妊に関連する酸化ストレス治療のためのn−アセチルシステインアミド(nacアミド) | |
FR2569105A1 (fr) | Procede de reproduction des corps cellulaires | |
Johnston et al. | The koala (Phascolarctos cinereus): a case study in the development of reproductive technology in a marsupial | |
Tollner et al. | Frozen-thawed rhesus sperm retain normal morphology and highly progressive motility but exhibit sharply reduced efficiency in penetrating cervical mucus and hyaluronic acid gel | |
AU2013277007B2 (en) | Aqueous moisturizers and lubircants and uses thereof | |
Castellini et al. | Effect of different number of frozen spermatozoa inseminated on the reproductive performance of rabbit does | |
CN101688859A (zh) | 精子活力的调节 | |
García-Vázquez et al. | Reproductive Biotechnologies Applied to Artificial Insemination in Swine | |
AU2018266135B2 (en) | Hydroxyurea to enhance sperm cells | |
Tilahun et al. | ETHIOPIAN VETERINARY ASSOCIATION (EVA) | |
Schiewe | Comparative studies of estrous synchronization, ovulation induction, luteal function and embryo cryopreservation in domestic sheep and application to related investigations of nondomestic ungulate species | |
Shuttleworth | Fertility of frozen-thawed dog sperm with the addition of homologous prostatic fluid or protein-free sperm TALP prior to intravaginal insemination of bitches | |
Ax et al. | EVALUATION AND FERTILITY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100301 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100301 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120904 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121203 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130304 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130716 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131015 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131022 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140116 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140218 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140320 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5507852 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |